Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer
Halda Therapeutics, a biotech company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics for cancer, has appointed Christian Schade as President, CEO, and Board member. Schade brings over 20 years of pharma and biotech industry experience, including leadership in clinical pipeline development and value-creating deals. Tim Shannon continues as Board Chairman.
Schade's appointment comes as Halda prepares to enter clinical trials, with the first RIPTAC therapeutic expected to begin trials in the first half of 2025. The company is focusing on developing therapies for prostate and breast cancer. Schade's previous roles include CEO of Aprea Therapeutics, Growth Partner at Flagship Pioneering, and executive positions at Novira, Omthera Pharmaceuticals, and Medarex.
Halda Therapeutics, un'azienda biotecnologica che sviluppa terapeutiche RIPTAC™ (Chimere a Targeting Indotto Regolato) per il cancro, ha nominato Christian Schade come Presidente, CEO e membro del Consiglio. Schade porta con sé oltre 20 anni di esperienza nell'industria farmaceutica e biotecnologica, inclusa la leadership nello sviluppo di pipeline cliniche e affari che creano valore. Tim Shannon continua come Presidente del Consiglio.
La nomina di Schade avviene mentre Halda si prepara a entrare negli studi clinici, con il primo terapeutico RIPTAC previsto per iniziare le prove nella prima metà del 2025. L'azienda si concentra sullo sviluppo di terapie per il cancro alla prostata e al seno. Le esperienze precedenti di Schade includono il ruolo di CEO di Aprea Therapeutics, Partner di Crescita presso Flagship Pioneering, e posizioni esecutive presso Novira, Omthera Pharmaceuticals e Medarex.
Halda Therapeutics, una empresa biotecnológica que desarrolla terapéuticas RIPTAC™ (Quimeras de Proximidad Inducida Regulada) para el cáncer, ha nombrado a Christian Schade como Presidente, CEO y miembro de la Junta. Schade aporta más de 20 años de experiencia en la industria farmacéutica y biotecnológica, incluido liderazgo en el desarrollo de pipelines clínicos y acuerdos que crean valor. Tim Shannon continúa como Presidente de la Junta.
El nombramiento de Schade se produce mientras Halda se prepara para entrar en ensayos clínicos, con el primer terapéutico RIPTAC esperado para comenzar ensayos en la primera mitad de 2025. La empresa se está centrando en desarrollar terapias para el cáncer de próstata y de mama. Los roles previos de Schade incluyen CEO de Aprea Therapeutics, Socio de Crecimiento en Flagship Pioneering, y puestos ejecutivos en Novira, Omthera Pharmaceuticals y Medarex.
Halda Therapeutics는 암 치료를 위한 RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) 치료제를 개발하는 생명공학 회사로, Christian Schade를 회장, CEO 및 이사회 멤버로 임명했습니다. Schade는 임상 파이프라인 개발 및 가치 창출 거래에서의 리더십을 포함하여 제약 및 생명공학 산업에서 20년 이상의 경험을 가지고 있습니다. Tim Shannon은 이사회 의장직을 계속 맡고 있습니다.
Schade의 임명은 Halda가 임상 시험에 들어가기 위해 준비하는 상황에서 이루어졌으며, 첫 번째 RIPTAC 치료제는 2025년 상반기에 임상 시험을 시작할 것으로 예상됩니다. 회사는 전립선 및 유방암 치료제 개발에 집중하고 있습니다. Schade의 이전 역할로는 Aprea Therapeutics의 CEO, Flagship Pioneering의 성장 파트너, Novira, Omthera Pharmaceuticals 및 Medarex의 임원직 등이 있습니다.
Halda Therapeutics, une entreprise biotechnologique développant des thérapeutiques RIPTAC™ (Chimères à Ciblage de Proximité Induit Régulé) pour le cancer, a nommé Christian Schade en tant que Président, PDG et membre du Conseil. Schade apporte plus de 20 ans d'expérience dans l'industrie pharmaceutique et biotechnologique, incluant un leadership dans le développement de pipelines cliniques et des accords créateurs de valeur. Tim Shannon continue comme Président du Conseil.
La nomination de Schade intervient alors que Halda se prépare à entrer dans des essais cliniques, avec le premier thérapeutique RIPTAC prévu pour commencer les essais dans la première moitié de 2025. L'entreprise se concentre sur le développement de thérapies pour le cancer de la prostate et du sein. Les précédents rôles de Schade incluent PDG d'Aprea Therapeutics, Partenaire de Croissance chez Flagship Pioneering, et des postes de direction chez Novira, Omthera Pharmaceuticals et Medarex.
Halda Therapeutics, ein Biotechnologieunternehmen, das RIPTAC™ (Regulierte induzierte Näherungszielchimeras) für Krebs entwickelt, hat Christian Schade zum Präsidenten, CEO und Vorstandsmitglied ernannt. Schade bringt über 20 Jahre Erfahrung in der Pharma- und Biotech-Industrie mit, einschließlich Führungspositionen in der klinischen Pipeline-Entwicklung und wertschöpfenden Geschäften. Tim Shannon bleibt Vorsitzender des Vorstands.
Schades Ernennung erfolgt, während Halda sich auf den Eintritt in klinische Studien vorbereitet, wobei die erste RIPTAC-Therapie voraussichtlich in der ersten Hälfte von 2025 mit den Studien beginnen wird. Das Unternehmen konzentriert sich auf die Entwicklung von Therapien für Prostata- und Brustkrebs. Zu Schades früheren Positionen gehören CEO von Aprea Therapeutics, Wachstumsbeauftragter bei Flagship Pioneering und Führungskräftepositionen bei Novira, Omthera Pharmaceuticals und Medarex.
- Appointment of experienced biotech leader Christian Schade as CEO
- Company preparing to enter clinical trials with first RIPTAC therapeutic in H1 2025
- Focus on developing therapies for prevalent cancers with unmet needs (prostate and breast cancer)
- Strong momentum and potential for pipeline expansion
- None.
Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company
Halda CEO Christian Schade (Photo: Business Wire)
“We are excited to welcome Chris to the role of Halda’s CEO and member of the Board. His strong track record building and leading biotech companies is ideally suited to Halda’s next stage of evolution to a clinical-stage cancer company,” said Tim Shannon, Chair of Halda’s Board of Directors and General Partner of Canaan Partners. “With Chris’ outstanding leadership, Halda is well positioned to realize the full potential of the RIPTAC modality, as the company advances therapeutics into clinical trials for patients with prostate cancer and breast cancer, two of the most prevalent cancer types with significant unmet needs for patients.”
"I am delighted to join the talented team at Halda that has made impressive progress advancing the RIPTAC platform to bring new cancer-fighting approaches to clinical development," said Mr. Schade. “This is a time of strong momentum for the company, particularly as the first RIPTAC therapeutic is on track to begin clinical trials in the first half of 2025. There are many exciting prospects ahead to expand Halda’s pipeline and explore business opportunities, as we leverage the RIPTAC platform to develop targeted oral cancer therapies to improve outcomes for cancer patients.”
Most recently, Chris was a Growth Partner at Flagship Pioneering since January 2023 where he worked with leaders at Flagship-founded biotech companies on organizational development, long-term strategy, financing, and business development. Previously, he was President and Chief Executive Officer and Board member of Aprea Therapeutics (Nasdaq: APRE) from 2016 to 2022, including as Chairman from 2020 to 2023. He led Aprea in developing its pipeline of anti-cancer therapies through the company’s IPO in 2019. Chris has also served in executive leadership positions at other biotech companies with emerging clinical candidates including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson; Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company focused on new therapies for dyslipidemia until it was acquired by AstraZeneca Plc; and, Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb. Earlier in his career, Chris was Managing Director at Merrill Lynch in
Currently, Chris serves on the boards of several biotechnology companies, including as Board Chair for Omega Therapeutics (Nasdaq: OMGA), Director at Valo Health, and Director at Integra LifeSciences (Nasdaq: IART) where he chairs the Audit and Finance Committees. He received an A.B. degree from
About Halda Therapeutics
Halda Therapeutics is a biotechnology company, founded by Professor Craig Crews from Yale University, that has developed a proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) modality that works by a novel “hold and kill” mechanism for the precision treatment of cancer. The novel mechanism of action of RIPTAC therapeutics is uniquely designed to address cancer’s ability to evolve bypass mechanisms of resistance, a common limitation of today’s precision oncology medicines. Our lead RIPTAC programs are in development for major solid tumor types, prostate cancer and breast cancer, with additional RIPTAC therapeutic programs in our pipeline to treat unmet medical needs in cancer. The company will initiate its Phase 1 trial in metastatic, castration-resistant prostate cancer (mCRPC) in 2025. Halda is led by a leadership team with deep expertise in bifunctional drug discovery, platform innovation and clinical development, and is located in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001848346/en/
Media Contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com
Source: Halda Therapeutics
FAQ
Who is the new CEO of Halda Therapeutics?
What is Halda Therapeutics' main focus?
When is Halda Therapeutics expected to begin clinical trials?
What is Christian Schade's background in the biotech industry?
